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Background
Ubiquilin-1 is a ubiquitin-like protein involved in the
pathogenesis of Alzheimer’s disease (AD) and other neuro-
degenerative disorders via different mechanisms. UBQLN1
UBQ-8i genetic variation associates with increased AD risk.
Ubiquilin-1 protein functions as a molecular chaperone
controlling amyloid precursor protein (APP) trafficking
and processing and presenilin (PS) levels and subcellular
targeting. Ubiquilin-1 harbors a ubiquitin-like (UBL)
domain interacting with the proteasome and a ubiquitin-
associated (UBA) domain binding polyubiquitinated
proteins. Thus, it may target polyubiquitinated proteins to
degradation. Alternative splicing of UBQLN1 generates
four transcript variants (TV) with varying domain struc-
tures, suggesting that diverse variants may specifically inter-
act with and regulate different proteins and cellular
functions.
Materials and methods
HEK293 or SH-SY5Y cells overexpressing APP751 were
transfected with ubiquilin-1 TVs containing myc and/ or
mRFP tags and PS1 or 0N4R-tau using Lipofectamine
®.
Cultured E18 embryonic cortical neurons from transgenic
APP/PS1 mice were transfected using magnetofection or
lentiviruses. Proteins of interest were assessed from pro-
tein lysates, membrane fractions, or immunoprecipitates
by Western blotting. Intracellular localization of proteins
was examined by confocal microscopy.
Results
We found that TV1, the full-length ubiquilin-1, and TV3,
containing an incomplete UBL domain, caused accumula-
tion of high-molecular-weight (HMW) PS1 and targeted
accumulated PS1 to intracellular inclusions termed aggre-
somes. TV3 induced PS1 accumulation and aggresomal
targeting more strongly than TV1, suggesting that TV3
may not target PS1 to proteasomal degradation as effi-
ciently as TV1. In addition, we discovered that TV1
increased the ε-site cleavage of APP and another PS/
g-secretase substrate, resulting in increased release of the
respective intracellular domains but no overt changes in
Ab levels. Interestingly, TV2, whose levels increase in AD
brain by the UBQ-8i variation, did not have a similar
effect. We next investigated whether ubiquilin-1 affects
the levels of tau, another key protein in AD and other
tauopathies. We observed that TV1 increased the levels
and phosphorylation status of tau. However, we found no
evidence for HMW-tau and tau did not localize in intra-
cellular inclusions similarly to PS1. Further induction of
protein accumulation by proteasomal inhibition did not
result in the formation of tau-containing inclusions nor
did it potentiate the increase in tau levels by TV1. We are
currently investigating the mechanisms by which ubiqui-
lin-1 regulates the AD-related proteins and the potential
subsequent implications in AD molecular pathogenesis
in vitro and in vivo.
Conclusions
Our data suggest that ubiquilin-1 functions as a modulator
of PS/g-secretase cleavage and as a molecular chaperone
for APR, PS1 and possibly tau. These findings agree well
with the previously suggested function for ubiquilin-1 as a
regulator of protein levels, degradation, and targeting to
inclusions. Our results further propose that different ubi-
quilin-1 TVs may have differential functions, which may
have important implications in the pathogenesis of AD
and other neurodegenerative disorders.
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